# Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

> **NCT03259308** · PHASE3 · TERMINATED · sponsor: **Shire** · enrollment: 279 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Ontamalimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03259308
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-05
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-10-06
- **Target enrollment:** 279 (ACTUAL)
- **Why stopped:** Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259308, "Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03259308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*